Litigation Details for Teva Pharmaceuticals International GmbH v. Lupin, Ltd. (D. Del. 2019)
✉ Email this page to a colleague
Teva Pharmaceuticals International GmbH v. Lupin, Ltd. (D. Del. 2019)
| Docket | ⤷ Subscribe | Date Filed | 2019-07-02 |
| Court | District Court, D. Delaware | Date Terminated | 2020-03-11 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Patents | 10,010,533; 10,052,385; 8,609,707; 9,000,021; 9,034,908; 9,144,568; 9,265,831; 9,572,796; 9,572,797; 9,572,887; 9,579,384; 9,597,397; 9,597,398; 9,597,399 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Teva Pharmaceuticals International GmbH v. Lupin, Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷ Subscribe and ⤷ Subscribe .
Details for Teva Pharmaceuticals International GmbH v. Lupin, Ltd. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2019-07-02 | 1 | Complaint | 384 patent”), 10,010,533 (the “’533 patent”); and 10,052,385 (the “’385 patent”) (collectively, the …INFRINGEMENT BY LUPIN OF U.S. PATENT NO. 10,010,533 UNDER 35 U.S.C. § 271(e)(2) …INFRINGEMENT BY LUPIN OF U.S. PATENT NO. 10,010,533 359. Plaintiffs incorporate…as the ’021 patent), and all patent rights claiming priority to those patents or patent applications …expiration of U.S. Patent Nos. 8,609,707 (the “’707 patent”); 9,265,831 (the “’831 patent”); 9,572,796 (the | External link to document |
| 2020-03-11 | 25 | Patent/Trademark Report to Commissioner of Patents | 9,597,399 B2; US 10,010,533 B2; US 10,052,385 B2. (Attachments: # 1 Patent Report Page 2, # 2 Patent Report Page… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s)US 8,609,707 B2…2019 11 March 2020 1:19-cv-01251 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-07-02 | 4 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,609,707 B2; US 9,000,021 …2019 11 March 2020 1:19-cv-01251 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-07-02 | 5 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,572,796 B2; US 9,572,797 …2019 11 March 2020 1:19-cv-01251 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-07-02 | 6 | Patent/Trademark Report to Commissioner of Patents | B2; US 9,597,399 B2; US 10,010,533 B2; US 10,052,385 B2. (nmg) (Entered: 07/03/2019) 2 July 2019 … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,597,398 B2…2019 11 March 2020 1:19-cv-01251 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
